Substituted [1,2,3]triazolo[4,5-D]pyrimidines as CDK inhibitors
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F10%3A10212657" target="_blank" >RIV/61989592:15310/10:10212657 - isvavai.cz</a>
Alternative codes found
RIV/61389030:_____/10:00353545
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Substituted [1,2,3]triazolo[4,5-D]pyrimidines as CDK inhibitors
Original language description
The present invention relates to a compound of formula I, or a pharmaceutically acceptable acid salt thereof. The invention further relates to the use of such compounds in the treatment of hyperproliferative skin disorders, viral infections, cancer, rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, restenosis, polycystic kidney disease, graft rejection, graft versus host disease and gout, or for psoriasis, parasitoses such as those caused by fungi or protists, or Alzheimer's disease.Further aspects of the invention relate to the use of such compounds in the inhibition of cell proliferation, in the induction of apoptosis, to modulate the activity of adrenergic and/or purinergic receptors or to suppress immunostimulation. The invention also relates to the use of 2,6,9-trisubstituted 8-azapurines in maintaining mammalian ooctyes at the germinal vesicle stage.
Czech name
—
Czech description
—
Classification
Type
P - Patent
CEP classification
CC - Organic chemistry
OECD FORD branch
—
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2010
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Patent/design ID
US7816350
Publisher
—
Publisher name
—
Place of publication
—
Publication country
—
Date of acceptance
Oct 19, 2010
Owner name
Institute of Experimental Botany ASCR, Lysolaje (CZ), Univerzita Palackeho v Olomouci, Olomouc (CZ)
Method of use
A - Výsledek využívá pouze poskytovatel
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence